PHAR · Pharming Group N.V.
$12.01
-0.85 (-6.61%)
At close · Jul 29
Earnings today
Market Cap
$8.43B
Shares
701.68M
Pharming Group N.V. Earnings Call Transcripts
Every quarterly earnings call for Pharming Group N.V. (PHAR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-07-30
Earnings conference call (announced in 6-K)
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-03-31
Pharming Group N.V. Q1 FY2026 Earnings Call
Positive tone
Joenja commercial growth and patient expansion
RUCONEST revenue decline and inventory dynamics
Pipeline programs in PIDs, CVID and mitochondrial disease
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Pharming Group N.V. Q3 FY2025 Earnings Call
Confident tone
Joenja/APDS franchise expansion
RUCONEST commercial growth
RUCONEST ex-U.S. withdrawal
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Pharming Group N.V. Q2 FY2025 Earnings Call
Confident tone
Joenja (leniolisib) commercialization in APDS
RUCONEST growth and market position
APDS patient pool expansion via VUS reclassification
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Pharming Group N.V. Q1 FY2025 Earnings Call
Confident tone
Joenja (leniolisib) commercial uptake and catalysts
RUCONEST revenue growth and commercial performance
G&A cost reduction initiative
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Pharming Group N.V. Q4 FY2024 Earnings Call
Confident tone
Joenja (leniolisib) launch and APDS franchise
RUCONEST revenue growth and HAE market position
Pipeline expansion into larger indications (APLS, CVID)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Pharming Group N.V. Q3 FY2024 Earnings Call
Positive tone
Joenja/leniolisib launch and growth
RUCONEST commercial performance
Financial performance and guidance
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Pharming Group N.V. Q2 FY2024 Earnings Call
Confident tone
Joenja launch momentum
RUCONEST performance and growth
Pipeline expansion / leniolisib indications
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Pharming Group N.V. Q1 FY2024 Earnings Call
Confident tone
Joenja/leniolisib launch in APDS
Revenue guidance and quarterly dynamics
RUCONEST franchise performance
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Pharming Group N.V. Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Pharming Group N.V. Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Pharming Group N.V. Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Pharming Group N.V. Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Pharming Group N.V. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Pharming Group N.V. Q3 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Pharming Group N.V. Q1 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q3
2021-09-30
Pharming Group N.V. Q3 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Pharming Group N.V. Q2 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–18 of 18 earnings calls